NKX2.5 Antibody Image: Coll Signaling tree of the otor o

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	Reactivity: H	Sensitivity: Endogenous	MW (kDa): 30-42	Source/Isotype: Rabbit	UniProt ID: #P52952	Entrez-Gene Id: 1482
Product Usage Information	2	Application Western Blotting Immunoprecipitation			Dilution 1:1000 1:50	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		NKX2.5 Antibody detects endogenous levels of total NKX2.5 protein.				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala71 of human NKX2.5 protein. Antibodies are purified by protein A and peptide affinity chromatography.				
Background		NKX2.5 is a member of the NKX homeobox transcription factor family. NKX2.5 plays an essential role in heart development and is among the earliest factors expressed in the cardiac lineage in developing embryos. Targeted disruption of the murine <i>Nkx2.5</i> gene results in abnormal heart morphogenesis, severe growth retardation, and embryonic lethality around E9.5 (1,2). Mutations in <i>NKX2.5</i> are likewise associated with several congenital heart conditions, such as atrial defect with atrioventricular conduction defects (ASD-AVCD) and Tetralogy of Fallot (TOF) (3,4). Transcriptional activation of <i>NKX2.5</i> is also associated with some B and T cell leukemias that result from chromosomal translocation (5-8).				
Background References		1. Lyons, I. et al. (1995) 2. Tanaka, M. et al. (199 3. Benson, D.W. et al. (1 4. Reamon-Buettner, S. 5. Nagel, S. et al. (2003) 6. Przybylski, G.K. et al. 7. Nagel, S. et al. (2007) 8. Su, X. et al. (2008) Ha	99) <i>Development</i> 1 999) <i>J Clin Invest</i> 1 M. and Borlak, J. (2) <i>Cancer Res</i> 63, 53 (2006) <i>Haematolo</i>) <i>Cancer Res</i> 67, 14	26, 1269-80. 04, 1567-73. 010) <i>Hum Mutat</i> 31, 118 29-34. <i>gica</i> 91, 317-21. 61-71.	35-94.	
Species Reacti	vity	Species reactivity is det	ermined by testing	g in at least one approve	ed application (e.g.,	western blot).
Western Blot Buffer		IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				
Applications Key		W: Western Blotting IP: Immunoprecipitation				
Cross-Reactivity Key		H: Human				
Trademarks and Patents		Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.				
		All other trademarks ar more information.	e the property of t	heir respective owners.	Visit cellsignal.com	/trademarks for
Limited Uses		Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.				
		approved, cleared, or li	censed by the FDA	se Only or a similar labe or other regulatory for duct for any diagnostic o	eign or domestic er	ntity, for any

any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products on services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.